Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright

H.C. Wainwright has lowered the price target for Rhythm Pharmaceuticals (RYTM) from $125 to $110. Despite this adjustment, the firm maintains a Buy rating following the company's recent Q4 results and positive Phase 3 trial data.

This price target reduction reflects a recalibration of long-term sales expectations. The positive data from the TRANSCEND trial indicates potential growth, but analysts are cautious about future sales trajectories.

Investors will be watching closely as Rhythm continues to release more data from its trials. The market's reaction to these developments could influence future price targets and investor confidence.